Company News Summary | 19 May 2021
Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified
Paradigm Biopharmaceuticals Achieves First Revenue
09:09:00 | Associate analysts
Original annuncemenet:PARADIGM ACHIEVES FIRST REVENUE
Paradigm Biopharmaceuticals announces that it has received first revenue through a physician prescription of Zilosul to patients via the TGA SAS. In Australia, injectable Pentosan Polysulfate Sodium (iPPS/Zilosul) is not currently available for sale. Injectable PPS for human use is only available to patients who qualify for inclusion into a Paradigm Sponsored clinical trial or via a treating physician applying for its use in patients via the TGA's SAS (Category B).
|This report appeared on www.morningstar.com.au||2021 Morningstar Australasia Pty Limited|
© Copyright 2021 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").